Pfizer says on surveillance for mid-size drug deals

<p>(Reuters) Pfizer Inc, that final week concluded to sell a baby formula business for roughly $12 billion, is on a hunt for companies with earnest new treatments for diabetes, cancer and neurological conditions, and peaceful to spend $4 billion or some-more apiece, association Chief Executive Ian Read said.
I have no seductiveness in a large consolidating deal, Read pronounced in an interview, referring to hulk exchange like Pfizers $67 billion squeeze of opposition U.S. drugmaker Wyeth in 2009, or a $60 billion partnership with Pharmacia in 2003.
Read pronounced Pfizer has an eye out for smaller bolt-on deals of roughly a same distance as a $3.6 billion squeeze of King Pharmaceuticals final year for a register of pain medicines.
Thats not a tough series around that (amount) or a mixed of that if it was an appealing asset, Read pronounced in an talk after Pfizer reported plain quarterly gain notwithstanding general foe that smashed sal...